Review Says Alzheimer’s Drug Class Ineffective — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Review finds little clinical benefit for a class of Alzheimer’s drugs
- Alzheimer’s experts criticize the analysis for lumping failed drugs with two newly approved treatments
Why it matters: Pharma firms risk losing market share as the review deems their drug class ineffective, while two newly approved treatments may capture more prescriptions, potentially reshaping insurance formularies and research funding.
Ask SkimNews
